SEC Form 4 · accession 0002114309-26-000007
NovaBridge Biosciences · NBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cong Claire Xu
Officer — EVP, Clinical Development
Period of report
Aug 30, 2026
Accepted (ET)
Sep 1, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001778016
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3,F4 | Aug 30, 2026 | M | 9,382 | — | A | 307,483 | D | |
| Ordinary SharesF1,F5,F6,F7 | Aug 31, 2026 | S | 3,282 | $0.79 | D | 304,201 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF8,F3,F9,F1 | — | Aug 30, 2026 | M | 4,079 | D | — | — | Ordinary Shares | 4,079 | 28,558 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
- F2Reported securities are represented by 4,079 ADSs.
- F3Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
- F4Reported securities are represented by 133,688 ADSs.
- F5Reported securities are represented by 1,427 ADSs.
- F6Reported sales price represents the converted sales price of the ADSs of $1.8186.
- F7Reported securities are represented by 132,261 ADSs.
- F8Reported securities represent ADSs.
- F9On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.